Thus, transcriptomics can reveal neuroinflammatory disorders sharing analogous biological pathways, indicating approved MS drugs to be considered in HAM/TSP, but also allow the identification of possible novel therapeutic targets, e.g., TGM2 or L3MBTL2 (Figure 7B). Here, L3MBTL2 is linked to myeloid sarcoma.